The HealthShares Infectious Disease ETF (Ticker: HHG) seeks to replicate as closely as possible, before expenses, the total return performance of the HealthShares Infectious Disease Index. The index is comprised of companies that are engaged in the research, clinical development and/or commercialization of therapeutic agents for the treatment of a wide variety of infectious diseases related to antibacterial, antifungal and antiviral indications, by means of small molecules, protein therapy and vaccines. Companies must have a minimum market capitalization greater than $100 million and less than $15 billion for at least two of the three proceeding quarters. Companies were equal weighted at the fund's inception, then allowed to float with the market thereafter. When the weight of an individual stock reaches 15% of the index value it is adjusted down to 10%, and when a stocks falls to 2.5% it is adjusted up to 5%. S&P is the administrator of HealthShares indexes.